Rationale and motivating factors for treatment-free remission in chronic myeloid leukemia

References

• NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 1.2016. [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2015 Sept 9 [cited 2016 May 23]; Available from: www.nccn.org/professionals/physician_gls/pdf/cml.pdf.
   Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011;103:553–561.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study. Blood. 2011;118: abstract 603.
   PubMed Web of Science ®Google Scholar
• Matsuki E, Ono Y, Tonegawa K, et al. Detailed investigation on characteristics of Japanese patients with chronic phase CML who achieved a durable CMR after discontinuation of imatinib—an updated result of the Keio STIM study. Blood. 2012;120: abstract 2788.
   Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–522.
   PubMed Web of Science ®Google Scholar
• Rea D, Rousselot P, Guilhot F, et al. Discontinuation of second generation (2G) tyrosine kinase inhibitors (TKI) in chronic phase (CP)-chronic myeloid leukemia (CML) patients with stable undetectable BCR-ABL transcripts. Blood. 2012;120: abstract 916.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–430.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Long term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 study. Blood. 2013;122: abstract 255.
   Google Scholar
• Saussele S, Richter J, Guilhot J, et al. First interim analysis of a pan-European STOP trial using standardized molecular criteria: results of the EURO-SKI trial. Haematologica. 2014;99: abstract LB2440.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Richter J, Guilhot J, et al. Interim analysis of a pan European stop tyrosine kinase inhibitor trial in chronic myeloid leukemia: the EURO-SKI study. Blood. 2014;124: abstract 151.
   PubMed Web of Science ®Google Scholar
• Rea D, Nicolini FE, Tulliez M, et al. Dasatinib or nilotinib discontinuation in chronic phase (CP)-chronic myeloid leukemia (CML) patients (pts) with durably undetectable BCR-ABL transcripts: interim analysis of the STOP 2G-TKI study with a minimum follow-up of 12 months—on behalf of the French CML Group Filmc. Blood. 2014;124: abstract 811.
   PubMed Web of Science ®Google Scholar
• Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2:e528–e535.
   PubMed Web of Science ®Google Scholar
• Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101:717–723.
   PubMed Web of Science ®Google Scholar
• Mori S, Le Coutre P, Abruzzese E, et al. Imatinib suspension and validation study: results at 24 months. Blood. 2015;126: abstract 2775.
   PubMed Web of Science ®Google Scholar
• Etienne G, Rea D, Guilhot J, et al. Long-term follow-up of the French 1 Stop Imatinib Study (STIM1) in chronic myeloid leukemia patients. Blood. 2015;126: abstract 345.
   Google Scholar
• Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell tranplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28:1888–1895.
   PubMed Web of Science ®Google Scholar
• Pavlu J, Szydlo RM, Goldman JM, et al. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood. 2011;117:755–763.
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087–1092.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Fort M, Etienne G, et al. Interferon alpha alone is able to cure chronic myeloid leukemia in a small subset of patients despite the persistence of leukemic cells: experience of long follow up after treatment discontinuation. Blood. 2010;116: abstract 2299.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Delbrel X, Cony-Makhoul P, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214–220.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003;97:1033–1041.
   PubMed Web of Science ®Google Scholar
• Erba HP. Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission. Am J Hematol. 2015;90:242–249.
   PubMed Web of Science ®Google Scholar
• Breccia M, Alimena G. Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett. 2014;347:22–28.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Etienne G. Deep molecular response in chronic myeloid leukemia: the new goal of therapy? Clin Cancer Res. 2014;20:310–322.
   PubMed Web of Science ®Google Scholar
• Ross DM, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. Br J Haematol. 2014;166:3–11.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Goldman JM, et al. International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM). Blood. 2008;112: abstract 186.
   Web of Science ®Google Scholar
• Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib versus imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044–1054.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Saglio G, Baccarani M, et al. Final study results of the phase 3 dasatinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056). Blood. 2014;124: abstract 152.
   Google Scholar
• Hughes TP, Larson RA, Kim DW, et al. Efficacy and safety of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: 6-year follow-up of ENESTnd. Haematologica. 2015;100: abstract P228.
   Web of Science ®Google Scholar
• Ariad Pharmaceuticals. Iclusig [package insert] 2015.
   Google Scholar
• Pfizer Inc. Bosulif [package insert] 2016.
   Google Scholar
• Brümmendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168:69–81.
   PubMed Web of Science ®Google Scholar
• Lipton JH, Chuah C, Guerci-Bresler A, et al. EPIC: a phase 3 trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML). Blood. 2014;124: abstract 519.
   PubMed Web of Science ®Google Scholar
• Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121:3818–3824.
   PubMed Web of Science ®Google Scholar
• Kalmanti L, Saussele S, Lauseker M, et al. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-Study IV. Leukemia. 2015;29:1123–1132.
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV. J Clin Oncol. 2014;32:415–423.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Gleevec [package insert] 2015.
   Google Scholar
• Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12:841–851.
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26:2197–2203.
   PubMed Web of Science ®Google Scholar
• Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123:1353–1360.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Sprycel [summary of product characteristics] 2015.
   Google Scholar
• Novartis Pharmaceuticals Corporation Tasigna [package insert] 2015.
   Google Scholar
• Hochhaus AH, Rosti G, Cross NCP, et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia. 2016;30:57–64.
   PubMed Web of Science ®Google Scholar
• A multicenter phase 3, open-label study of bosutinib versus imatinib in adult patients with newly diagnosed chronic phase chronic myelogenous leukemia [Internet]. Bethesda, MD: ClinicalTrials.gov; 2015 Sept 16 [cited 2016 Apr 25]; Available from: https://clinicaltrials.gov/ct2/show/NCT02130557
   Google Scholar
• Gambacorti-Passerini C, Brümmendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol. 2014;89:732–742.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood. 2014;124: abstract 3135.
   Web of Science ®Google Scholar
• Shah NP, Rousselot P, Schiffer CA, et al. Seven-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia receiving dasatinib in study CA180-034, final study results. Blood. 2014;124: abstract 520.
   Web of Science ®Google Scholar
• Hughes TP, Cervantes F, Leber B, et al. ENESTcmr 4-year results: patients with chronic myeloid leukemia in chronic phase and residual disease more likely to achieve deep molecular response following switch to nilotinib. Haematologica. 2015;100: abstract P229.
   Web of Science ®Google Scholar
• le Coutre PD, Shah S, De Souza CA, et al. Final LASOR results: switch to nilotinib in patients with chronic myeloid leukemia in chronic phase and suboptimal cytogenetic response to frontline imatinib. Haematologica. 2015;100: abstract P232.
   Web of Science ®Google Scholar
• Tanimoto M, Miyamura K, Miyamoto T, et al. Final results from SENSOR: switch to nilotinib after molecular suboptimal response (SoR) to frontline imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood. 2014;124: abstract 1815.
   Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–884.
   PubMed Web of Science ®Google Scholar
• Etienne G, Dulucq S, Nicolini FE, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib frontline therapy. Haematologica 2014;99:458–464.
   PubMed Web of Science ®Google Scholar
• Falchi L, Kantarjian HM, Wang X, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88:1024–1029.
   PubMed Web of Science ®Google Scholar
• Kuwabara A, Babb A, Ibrahim A, et al. Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response. Blood. 2010;116:1014–1016.
   PubMed Web of Science ®Google Scholar
• Koskenvesa P, Kreutzman A, Rohon P, et al. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol. 2014;92:413–420.
   PubMed Web of Science ®Google Scholar
• Rea D, Dulphy N, Henry G, et al. Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation In patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from Immunostim, on behalf of STIM Investigators. Blood. 2013;122: abstract 856.
   PubMed Web of Science ®Google Scholar
• Ilander M, Schlums H, Olsson-Stromberg U, et al. Mature, adaptive-like CD56DIM NK cells in chronic myeloid leukemia patients in treatment free remission. Blood. 2015;126: abstract 343.
   Web of Science ®Google Scholar
• Burchert A, Inselmann S, Saussele S, et al. Frequency of CTLA-4 receptor ligand (CD86, B7.2)-positive plasmacyoid dendritic cells predicts risk of disease recurrence after tyrosine-kinase inhibitor discontinuation in chronic myeloid leukemia: results from a prospective substudy of the Euroski trial. Blood. 2015;126: abstract 599.
   PubMed Web of Science ®Google Scholar
• Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–325.
   PubMed Web of Science ®Google Scholar
• Tang M, Gonen M, Quintas-Cardama A, et al. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 2011;118:1622–1631.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Rusakiewicz S, Routy B, et al. Immunological off-target effects of imatinib. Nat Rev Clin Oncol 2016;13:431–446.
   PubMed Web of Science ®Google Scholar
• Burchert A, Saussele S, Eigendorff E, et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015;29:1331–1335.
   PubMed Web of Science ®Google Scholar
• Tasigna and interferon alpha evaluation initiated by the German Chronic Myeloid Leukemia Study Group—the TIGER study [Internet]. Bethesda, MD: ClinicalTrials.gov; 2014 Dec 4 [cited2013 Sept 12]; Available from: https://clinicaltrials.gov/ct2/show/NCT01657604
   Google Scholar
• Open-label study evaluating dasatinib therapy discontinuation in patients with chronic phase chronic myeloid leukemia with stable complete molecular response (DASFREE) [Internet]. Bethesda, MD: ClinicalTrials.gov; 2013 May 8 [cited2013 Sep 9]; Available from: https://clinicaltrials.gov/ct2/show/NCT01850004
   Google Scholar
• Mahon FX, Baccarani M, Mauro MJ, et al. Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath. J Clin Oncol. 2014;32: abstract TPS7124.
   Web of Science ®Google Scholar
• Ritchie EK, Catchatourian R, Klisovic RB, et al. Rapid achievement of MR4.5 after switching from imatinib (IM) to nilotinib (NIL) in patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP): preliminary results from ENESTgoal. Blood. 2015;126: abstract 4050.
   Web of Science ®Google Scholar
• Rea D, Gianantonio R, Cross NCP, et al. ENESTpath: a phase III study to assess the effect of nilotinib treatment duration on treatment-free remission in chronic-phase chronic myeloid leukemia patients previously treated with imatinib: interim analysis from the first year of induction phase. Blood. 2015;126: abstract 4040.
   Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28–37.
   PubMed Web of Science ®Google Scholar
• Cross NCP, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999–1003.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27:1310–1315.
   PubMed Web of Science ®Google Scholar
• Laneuville P, Baccarani M, Cortes JE, et al. Analysis of patients (pts) with chronic phase chronic myeloid leukemia (CML-CP) who develop pleural effusion on first-line dasatinib: management and outcomes. J Clin Oncol. 2011;29: abstract 6605.
   Google Scholar
• Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128–2137.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123:494–500.
   PubMed Web of Science ®Google Scholar
• Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204–3212.
   PubMed Web of Science ®Google Scholar
• Rousselot P, Mollica L, Guerci-Bresler A, et al. Dasatinib daily dose optimization based on residual drug levels resulted in reduced risk of pleural effusions and high molecular response rates: final results of the randomized Optim dasatinib trial. Haematologica. 2014;99: abstract S678.
   Web of Science ®Google Scholar
• Guérin A, Chen L, Ionescu-Ittu R, et al. Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin. 2014;30:2317–2328.
   PubMed Web of Science ®Google Scholar
• Williams LA, Gonzalez AGG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013;122:641–647.
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011;118:4554–4560.
   PubMed Web of Science ®Google Scholar
• Boquimpani CM, Szczudlo T, Mendelson E, et al. Attitudes and perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR). Blood. 2014;124: abstract 4547.
   Web of Science ®Google Scholar
• Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Reply to J. Richter et al. J Clin Oncol. 2014;32:2823–2825.
   PubMed Web of Science ®Google Scholar
• Richter J, Söderlund S, Lübking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821–2823.
   PubMed Web of Science ®Google Scholar
• Ishii Y, Hagihara M, Ando T, et al. Musculoskeletal pain may be associated with imatinib withdrawal syndrome in chronic myeloid leukemia. Leuk Lymphoma. 2016;57:496–497.
   PubMed Web of Science ®Google Scholar
• Sanford D, Kyle R, Lazo-Langner A, et al. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol. 2014;21:e241–e249.
   PubMed Web of Science ®Google Scholar
• Goldberg S, Hamarman S. Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy. Blood. 2015;126: abstract 1584.
   PubMed Web of Science ®Google Scholar
• Kyle RM, Lazo-Langner A, Xenocostas A, et al. Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Blood. 2012;120: abstract 4274.
   Web of Science ®Google Scholar
• Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111:5505–5508.
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Ault P, et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib. Blood. 2008;112: abstract 3230.
   Web of Science ®Google Scholar
• Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90:1111–1115.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Sprycel [package insert] 2015.
   Google Scholar
• Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121:4439–4442.
   PubMed Web of Science ®Google Scholar
• Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32:306–311.
   PubMed Web of Science ®Google Scholar
• Lee SE, Choi SY, Bang JH, et al. Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib. Am J Hematol. 2013;88:449–454.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–1820.
   PubMed Web of Science ®Google Scholar
• Radich JP. How I monitor residual disease in chronic myeloid leukemia. Blood. 2009;114:3376–3381.
   PubMed Web of Science ®Google Scholar